A Phase I Trial of TGR-1202, a Next Generation Once Daily PI3K Delta Inhibitor, in Combination with Brentuximab Vedotin, in Patients with Relapsed/Refractory Hodgkins Lymphoma
Started December 5, 2016
82
Combination of Ublituximab, TGR-1202 and Bendamustine Demonstrates Significant Activity in Patients with Advanced DLBCL and Follicular Lymphoma.
Started December 5, 2016
82
Silencing cMyc Translation as a Therapeutic Strategy Through Targeting PI3K Delta and CK1 Epsilon in Hematological Malignancies.
Started December 4, 2016
83
Modulation of T cell Compartment in a Preclinical CLL Murine Model by a Selective PI3K delta inhibitor, TGR-1202.
Started December 4, 2016
66
Clinical Activity and Safety Profile of TGR-1202, a Novel Once Daily PI3K- Delta Inhibitor, in Patients with CLL and B-Cell Lymphoma.
Started December 8, 2015
197
A Phase I Trial of TGR-1202, a Next Generation Once Daily PI3K-Delta Inhibitor in Combination with Obinutuzumab Plus Chlorambucil, in Patients with Chronic Lymphocytic Leukemia.
Started December 8, 2015
215
Disruption of the mTOR-eIF4F Axis By Selectively Targeting PI3Kdelta and Proteasome Potently Inhibits Cap Dependent Translation of c-Myc in Aggressive Lymphomas.
Started December 8, 2015
179
Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib is Highly Active in Patients with Relapsed and/or Refractory Mantle Cell Lymphoma: Results of a Phase II Trial.
Started December 8, 2015
203
Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib is Highly Active in Patients with Relapsed and/or Refractory Mantle Cell Lymphoma: Results of a Phase II Trial.
Started December 5, 2015
71
Ublituximab + TGR-1202 Demonstrates Activity and a Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL: Phase I Results.
Started March 8, 2015
59
The PI3K-delta Inhibitor TGR-1202 in Combination with Brentuximab Vedotin (SGN-35) Synergistically Inhibits Tubulin Polymerization and Exerts Potent Antitumor Effects in NOD/SCID Mice with Hodgkin Lymphoma Cell Line Xenografts.
Started December 9, 2014
58
Complementary Targeting of PI3K and the Proteasome Causes Potent Inhibition of mTORC1 and NF-kappaB in Models of B- and T-Cell Lymphoma.
Started December 9, 2014
58